Qu Biologics   Report issue

For profit Phase 2
Founded: Burnaby Canada (2007)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2013
NCT01809275
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Qu Biologics Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

qbeco (3 trials)

qbkpn (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Crohn Disease (Phase 2)

Inflammatory Bowel Diseases (Phase 2)

Intestinal Diseases (Phase 2)

Lung Neoplasms (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2